Since I am interested in Eisai's corporate governance initiatives in the ESG meeting on Dec 21, this article would like to analyze them in conjunction with the situation of pharmaceutical companies.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.